# DXP-106 in Solid Tumor Patients.

> **NCT07532018** · PHASE1 · RECRUITING · sponsor: **Singlomics Biopharmaceuticals Zhuhai Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Solid Tumor
- Cancer

## Interventions

- **DRUG:** DXP-106

## Key facts

- **NCT ID:** NCT07532018
- **Lead sponsor:** Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2028-02
- **Final completion:** 2028-03
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07532018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07532018, "DXP-106 in Solid Tumor Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07532018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*